Minimizing systemic inflammation during cardiopulmonary bypass in the pediatric population.
about
A Single-Center Analysis of Methylprednisolone Use during Pediatric Cardiopulmonary Bypass.Artificial organs 2014: a year in review.Key Points for Curbing Cardiopulmonary Bypass Inflammation.Systemic inflammatory response syndrome after pediatric congenital heart surgery: Incidence, risk factors, and clinical outcome.Preoperative asymptomatic leukocytosis and postoperative outcome in cardiac surgery patients.Hypothermia During Cardiopulmonary Bypass Increases Need for Inotropic Support but Does Not Impact Inflammation in Children Undergoing Surgical Ventricular Septal Defect Closure.A prospective randomized trial comparing the clinical effectiveness and biocompatibility of heparin-coated circuits and PMEA-coated circuits in pediatric cardiopulmonary bypass.Activation of the lectin pathway of complement by cardiopulmonary bypass contributes to the development of systemic inflammatory response syndrome after paediatric cardiac surgery.Promotion of anoxia-reoxygenation-induced inflammation and permeability enhancement by nicotinamide phosphoribosyltransferase-activated MAPK signaling in human umbilical vein endothelial cells.Dr. Yves Durandy, February 20, 1947-October 6, 2016.Effects of propofol and isoflurane on haemodynamics and the inflammatory response in cardiopulmonary bypass surgery.Lung ultrasound profile after cardiopulmonary bypass in paediatric cardiac surgery: first experience in a simple cohort.The Relative Citation Ratio: Measuring Impact of Publications From an International Conference With a New NIH Metric.Timing of Haemophilus influenzae type b vaccination after cardiac surgery.Intravenous morphine versus intravenous paracetamol after cardiac surgery in neonates and infants: a study protocol for a randomized controlled trial.
P2860
Q36243740-AB4C5272-2982-4260-AE1F-50E3D7F4EA36Q38383421-6BA34191-24D7-48F6-B8ED-661F4CE34172Q38824796-6496F44F-B167-4A4C-845F-B4AE980BB32CQ39120987-00E41341-7791-46A8-9499-40611680666EQ40066370-E4006395-EC33-4453-884F-D5C6BFBF4BE2Q40306607-593B02FE-AEE6-4497-A419-3ECA9A6EE003Q40675871-CEDB597F-7717-42A7-8B3D-E012C5C5282AQ40857844-0B7E61D7-9DFC-4126-A6B6-BA9E4E2287CDQ47099439-1E4B55F9-032D-4EE8-B039-52971F61F63AQ47589773-D7962103-DCD4-47E4-A8B4-021F24A81DE8Q47633983-85A73812-EAF3-4036-9AE2-8814448B41CDQ48008145-E9B7DAB8-D360-4D91-B3AD-BF4BD8C11BDEQ48136394-19F22DEF-8398-4E5D-8DDC-74FD31603AD7Q54693402-970334B9-F31D-42E4-A0A9-8915415CD0BDQ55266754-BF7C0803-9C96-40D3-BA59-4449C9B3DD6C
P2860
Minimizing systemic inflammation during cardiopulmonary bypass in the pediatric population.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Minimizing systemic inflammati ...... s in the pediatric population.
@en
type
label
Minimizing systemic inflammati ...... s in the pediatric population.
@en
prefLabel
Minimizing systemic inflammati ...... s in the pediatric population.
@en
P2860
P356
P1433
P1476
Minimizing systemic inflammati ...... s in the pediatric population.
@en
P2093
Yves Durandy
P2860
P356
10.1111/AOR.12195
P577
2013-10-31T00:00:00Z